Menu
Three Breast Woman Jasmine Tridevil is a Hoax

Three Breast Woman Jasmine Tridevil is a Hoax

iPhone 6 Plus Has Not the Best Smartphone Screen

iPhone 6 Plus Has Not the Best Smartphone Screen

Amber Heard Topless Photo Leaked

Amber Heard Topless Photo Leaked

Kim Kardashian Leaked Photos Backlash

Kim Kardashian Leaked Photos Backlash

Stephanie Beaudoin Dubbed Worlds Hottest Criminal

Stephanie Beaudoin Dubbed Worlds Hottest Criminal

Merck's Vorapaxar Gets Positive FDA Review

Jan 13 2014, 2:31pm CST | by , in News

 
 

A few years ago a novel antiplatelet agent from Merck seemed all but dead. Vorapaxar, a thrombin receptor antagonist, was widely thought to have no future after unacceptably high serious bleeding rates were found in two large clinical trials studying the drug in a wide variety of acute and chronic cardiovascular patients. But hopes for the drug resurfaced with a new analysis of one of those trials, the TRA2P trial. Now the FDA appears willing to give the drug a renewed lease on life.

On Wednesday the Cardiovascular and Renal Drugs Advisory Committee will discuss the new drug application for vorapaxar (proposed trade name Zontivity) for a considerably narrower indication than initially hoped by the company.  The proposed indication is as an adjunctive therapy for the reduction of atherothrombotic events in patients with a history of myocardial infarction (MI). The company also wants to claim the drug leads to a  reduction of the combined endpoint of cardiovascular death, MI, stroke, and urgent coronary revascularization.

In the full TRA2P trial, 26,449 patients with a history of MI, ischemic stroke, or peripheral arterial disease were randomized to either vorapaxar or placebo in addition to standard therapy. Vorapaxar was found to be effective in cutting the rate of CV death, MI, or stroke. But it was also associated with a doubling of the very serious complication of intracranial bleeding. This finding, along with the high rate of bleeding complications and intracranial hemorrhage that occurred in the TRACER trial in acute coronary syndrome patients, seemed likely to doom the drug.

But TRA2P was redesigned in midcourse based on Data and Safety Monitoring Board concerns about patients with a history of stroke. Patients with stroke were no longer allowed to enter the trial. In the subgroup analysis of the 17,779  patients with a history of myocardial infarction and no history of stroke, there was a significant reduction in cardiovascular events with no increase in intracranial bleeding.

In general, as I’ve noted before, a substudy does not provide sufficient evidence to support an NDA for a novel drug. But the TRA2P substudy was larger than is usually found in the entire population of most clinical trials. The FDA reviewers conclude that the “results are sufficient to establish the effectiveness of vorapaxar for its proposed indication in patients with prior MI and support the Applicant’s proposal not to include patients with prior stroke in the target population.”

The FDA will webcast the entire session on Wednesday. (Click here for webcast information.)

Source: Forbes

You Might Also Like

Updates

Shopping Deals

 
 
 

<a href="/latest_stories/all/all/31" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.

 

 

Comments

blog comments powered by Disqus

Latest stories

Mariska Hargitay says that Chris Meloni helped her out
Mariska Hargitay says that Chris Meloni helped her out
Mariska Hargitay who is a regular fixture on Law & Order: SVU has said that Chris Meloni helped her out in getting better at her game.
 
 
Kelly Osbourne gets Sentimental while speaking of Joan Rivers
Kelly Osbourne gets Sentimental while speaking of Joan Rivers
Kelly Osbourne of The Osbournes got sentimental while speaking of the late Joan Rivers who was with her on The Fashion Police.
 
 
Iggy Pop to Talk About Free Music in John Peel Lecture
Iggy Pop to Talk About Free Music in John Peel Lecture
Iggy Pop is going to deliver John Peel Lecture this year. He will talk about free music in his lecture on 13th October.
 
 
Melissa Gorga Loves Home Building on RHONJ
Melissa Gorga Loves Home Building on RHONJ
Melissa Gorga Loves Home Building on RHONJ
 
 
 

About the Geek Mind

The “geek mind” is concerned with more than just the latest iPhone rumors, or which company will win the gaming console wars. I4U is concerned with more than just the latest photo shoot or other celebrity gossip.

The “geek mind” is concerned with life, in all its different forms and facets. The geek mind wants to know about societal and financial issues, both abroad and at home. If a Fortune 500 decides to raise their minimum wage, or any high priority news, the geek mind wants to know. The geek mind wants to know the top teams in the National Football League, or who’s likely to win the NBA Finals this coming year. The geek mind wants to know who the hottest new models are, or whether the newest blockbuster movie is worth seeing. The geek mind wants to know. The geek mind wants—needs—knowledge.

Read more about The Geek Mind.